Cargo Therapeutics Financials
This page shows Cargo Therapeutics (CRGX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Cargo Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cargo Therapeutics carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 13.79, Cargo Therapeutics holds $13.79 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Cargo Therapeutics generates a -46.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -24.2% the prior year.
Cargo Therapeutics passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Cargo Therapeutics generates $0.83 in operating cash flow (-$139.7M OCF vs -$167.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Cargo Therapeutics's EBITDA was -$184.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 94.0% from the prior year.
Cargo Therapeutics reported -$167.5M in net income in fiscal year 2024. This represents a decrease of 70.7% from the prior year.
Cargo Therapeutics earned $-3.72 per diluted share (EPS) in fiscal year 2024. This represents an increase of 77.5% from the prior year.
Cash & Balance Sheet
Cargo Therapeutics generated -$144.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 61.2% from the prior year.
Cargo Therapeutics held $64.4M in cash against $0 in long-term debt as of fiscal year 2024.
Cargo Therapeutics had 46M shares outstanding in fiscal year 2024. This represents an increase of 11.7% from the prior year.
Margins & Returns
Cargo Therapeutics's ROE was -46.5% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 22.3 percentage points from the prior year.
Capital Allocation
Cargo Therapeutics invested $143.4M in research and development in fiscal year 2024. This represents an increase of 89.2% from the prior year.
Cargo Therapeutics invested $4.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 46.3% from the prior year.
CRGX Income Statement
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $7.5M-75.5% | $30.6M | N/A | $35.9M-4.1% | $37.5M+22.8% | $30.5M | N/A | $22.2M |
| SG&A Expenses | $8.3M-27.9% | $11.5M | N/A | $11.2M-5.7% | $11.9M+15.1% | $10.3M | N/A | $6.5M |
| Operating Income | -$52.9M+40.2% | -$88.4M | N/A | -$47.1M+4.5% | -$49.3M-20.9% | -$40.8M | N/A | -$28.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$49.9M+40.9% | -$84.5M | N/A | -$41.9M+5.5% | -$44.3M-23.8% | -$35.8M | N/A | -$35.5M |
| EPS (Diluted) | $-1.04+41.2% | $-1.77 | N/A | $-0.88+13.7% | $-1.02-17.2% | $-0.87 | N/A | $-47.37 |
CRGX Balance Sheet
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $258.6M-28.6% | $362.0M-12.6% | $414.1M-8.2% | $451.0M-8.0% | $490.0M+16.0% | $422.4M-6.8% | $453.0M+449.7% | $82.4M |
| Current Assets | $258.6M-20.4% | $324.8M-5.9% | $345.0M-15.9% | $410.0M-8.5% | $448.1M+17.9% | $379.9M-7.2% | $409.5M+545.7% | $63.4M |
| Cash & Equivalents | $107.7M+74.4% | $61.8M-4.1% | $64.4M-9.5% | $71.2M-53.7% | $153.6M+88.4% | $81.5M-79.9% | $405.7M+572.4% | $60.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $20.9M-73.7% | $79.5M+47.7% | $53.8M+7.5% | $50.1M-7.1% | $53.9M+9.5% | $49.2M+3.3% | $47.6M-75.1% | $191.7M |
| Current Liabilities | $20.9M-59.4% | $51.6M+106.0% | $25.0M+15.6% | $21.6M-18.1% | $26.4M+16.7% | $22.6M+7.0% | $21.2M-48.6% | $41.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $237.7M-15.8% | $282.5M-21.6% | $360.2M-10.1% | $400.9M-8.1% | $436.1M+16.9% | $373.2M-7.9% | $405.4M+470.8% | -$109.3M |
| Retained Earnings | -$447.1M-12.6% | -$397.1M-27.0% | -$312.6M-17.0% | -$267.2M-18.6% | -$225.3M-24.5% | -$181.0M-24.7% | -$145.1M-28.4% | -$113.1M |
CRGX Cash Flow Statement
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$77.4M-105.3% | -$37.7M-8.0% | -$34.9M+12.0% | -$39.6M-12.9% | -$35.1M-16.4% | -$30.1M-4.0% | -$29.0M-24.8% | -$23.2M |
| Capital Expenditures | $99K-74.1% | $382K-39.4% | $630K-40.8% | $1.1M-27.2% | $1.5M+13.5% | $1.3M-50.7% | $2.6M-27.4% | $3.6M |
| Free Cash Flow | -$77.5M-103.5% | -$38.1M-7.2% | -$35.5M+12.7% | -$40.7M-11.3% | -$36.5M-16.3% | -$31.4M+0.5% | -$31.6M-17.8% | -$26.8M |
| Investing Cash Flow | $123.4M+252.0% | $35.0M+24.0% | $28.3M+165.5% | -$43.2M-1239.1% | $3.8M+101.3% | -$294.0M-9784.2% | -$3.0M+23.8% | -$3.9M |
| Financing Cash Flow | $5K-86.8% | $38K+121.3% | -$178K-144.3% | $402K-99.6% | $103.3M+99474.0% | -$104K-100.0% | $377.9M+738.0% | $45.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CRGX Financial Ratios
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -21.0%+8.9pp | -29.9% | N/A | -10.4%-0.3pp | -10.2%-0.6pp | -9.6% | N/A | N/A |
| Return on Assets | -19.3%+4.0pp | -23.3% | N/A | -9.3%-0.2pp | -9.0%-0.6pp | -8.5% | N/A | -43.0% |
| Current Ratio | 12.37+6.1 | 6.30-7.5 | 13.79-5.2 | 18.95+2.0 | 16.96+0.2 | 16.78-2.6 | 19.35+17.8 | 1.54 |
| Debt-to-Equity | 0.09-0.2 | 0.28+0.1 | 0.15+0.0 | 0.120.0 | 0.120.0 | 0.13+0.0 | 0.12+1.9 | -1.75 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Cargo Therapeutics profitable?
No, Cargo Therapeutics (CRGX) reported a net income of -$167.5M in fiscal year 2024.
What is Cargo Therapeutics's EBITDA?
Cargo Therapeutics (CRGX) had EBITDA of -$184.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cargo Therapeutics's return on equity (ROE)?
Cargo Therapeutics (CRGX) has a return on equity of -46.5% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Cargo Therapeutics's free cash flow?
Cargo Therapeutics (CRGX) generated -$144.2M in free cash flow during fiscal year 2024. This represents a -61.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cargo Therapeutics's operating cash flow?
Cargo Therapeutics (CRGX) generated -$139.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Cargo Therapeutics's total assets?
Cargo Therapeutics (CRGX) had $414.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Cargo Therapeutics's capital expenditures?
Cargo Therapeutics (CRGX) invested $4.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Cargo Therapeutics spend on research and development?
Cargo Therapeutics (CRGX) invested $143.4M in research and development during fiscal year 2024.
What is Cargo Therapeutics's current ratio?
Cargo Therapeutics (CRGX) had a current ratio of 13.79 as of fiscal year 2024, which is generally considered healthy.
What is Cargo Therapeutics's debt-to-equity ratio?
Cargo Therapeutics (CRGX) had a debt-to-equity ratio of 0.15 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cargo Therapeutics's return on assets (ROA)?
Cargo Therapeutics (CRGX) had a return on assets of -40.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Cargo Therapeutics's cash runway?
Based on fiscal year 2024 data, Cargo Therapeutics (CRGX) had $64.4M in cash against an annual operating cash burn of $139.7M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cargo Therapeutics's Piotroski F-Score?
Cargo Therapeutics (CRGX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cargo Therapeutics's earnings high quality?
Cargo Therapeutics (CRGX) has an earnings quality ratio of 0.83x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cargo Therapeutics?
Cargo Therapeutics (CRGX) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.